Public Policy Letters, Statements, Legal Briefs, & Other Responses
-
Sign-on Letter to Congressional Leadership Concerning the VALID Act
-
ACMG Comments on FDA Draft Guidance for Products Incorporating Genome Editing
-
Group Sign-on Letter Concerning the VALID Act of 2022 Discussion Draft
-
ACMG Response to Opposing Inclusion of the VALID Act in the FDASLA Act
-
Group Sign-On Letter Urging CLIAC to Discuss CLIA Modernization
-
Group Sign-On Letter Supporting the VITAL Act
-
ACMG Letter to Congress Concerning the Verifying Accurate Leading-edge IVCT Development (VALID) Act
-
Group Sign-on Letter to HHS Supporting Clarification of LDT Regulatory Process
-
ACMG Comments to Congress Concerning the Verifying Accurate Leading-edge IVCT Development (VALID) Act Discussion Draft
-
ACMG Letter to Congress Concerning the FDA Technical Assistance for the Diagnostic Accuracy and Innovation Act (DAIA)